UK drug industry responds to concerns over Innovative Medicines Fund

25 August 2023

The trade body for the British pharmaceutical industry has issued a response to a report from the Journal of Royal Society of Medicine, which raised concerns about the Innovative Medicines Fund.

Introduced in June 2022, the Innovative Medicines Fund made up to £340 million ($430 million) available for the acquisition of the most promising medicines in order to fast-track them to patients.

Building on the UK’s Cancer Drugs Fund, which provided early access for more than 80,000 people to life-extending or potentially life-saving drugs, the new fund was intended to facilitate managed access agreements for treatments including for spinal muscular atrophy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK